Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Don W Stone who wrote (177)	11/2/1997 11:36:00 AM
From: Haolin Ni	Respond to of 645

Hi, Don, You are right that trading AVIR takes a lot of guts and luck but fundermentally, AVIR has no earning to support it and its products s are non-big deals if you read my posts in July. I am very sorry for those who brought AVIR around $30. I just could not understand people using long term investments to comfort themself when reality shows opposite way. I am sure you will see AVIR will drop under $20 in the winter because reality has teching investors lessons that high price (like AVIR) with no earning support could not maintaince overvalued price for a long time although it could go up sometime when market is hot, such as DNA, ZITL, GERN and AVIR but it will not happened again in same stocks. Some new black horse will come out one day. Only those companies have solid earning will have great future. I have long term positions in LGND, INTC and CREAF and belive they are much better than AVIR in long run.

To: Don W Stone who wrote (177)	11/14/1997 11:10:00 AM
From: Vector1	Read Replies (2) \| Respond to of 645

UPDATE A possible competitor to Aviron' s cold-adapted influenza virus vaccine announced negative Phase II results. The following is a summary of a Robby Stephens report I reviewed today. ---- Pasteur Merieux Connaught and Virus Research Institute (VRII $5 3/8, -3 1/2) announced preliminary Phase II results of an influenza vaccine being developed by the companies. In the Phase II study, in 430 elderly adults received a shot with either standard flu vaccine or flu vaccine plus VRII' s Adjumer. Although the companies have not disclosed details of the results, they did state that the Adjumer vaccine appears to be well tolerated. They also disclosed that the immunogenicity results (i.e., protective effects) were not as good as had been observed in a previous Phase I study. In the Phase II study, the degree of improvement in immune response in the Adjumer-treated patients was less than the improvement in the Phase I trial. Moreover, the immunogenicity in the control arm was higher in the Phase II than in the Phase I trial. The two companies are continuing to assess the Phase II results and will determine what next steps are appropriate. It is clear, however, that the development time line for Adjumer has been slowed.